Literature DB >> 28608731

Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx.

Danielle L Gainor1, Emily Marchiano1, Emily Bellile2, Matthew E Spector1, Jeremy M G Taylor2, Gregory T Wolf1, Norman D Hogikyan1, Mark E Prince1, Carol R Bradford1, Avraham Eisbruch3, Francis Worden4, Andrew G Shuman1.   

Abstract

Objective Emerging data have demonstrated suboptimal outcomes among patients with stage II larynx cancer. Our objective is to report survival outcomes for T2N0M0 larynx cancer and to determine the cause-specific survival. Study Design Case series with planned data collection. Setting Tertiary academic center. Subjects Adults with T2N0M0 squamous cell carcinoma of the larynx treated with curative intent. Methods A head and neck cancer epidemiology database was queried for eligible subjects from 2003 to 2014. Data were extracted from the electronic medical record and research database, and survival analyses were performed. Results Thirty-four patients with previously untreated stage II larynx cancer were identified (median follow-up 48 months). Patients included 27 males and 7 females with a mean age of 59 years. The majority of tumors arose from the glottis (59%). Of the cohort, 12% were treated with surgery, 65% radiation therapy, and 24% chemoradiation therapy. The estimated 2-year overall survival was 81%, (95% confidence interval [CI], 59%-92%), disease-specific survival was 91% (95% CI, 69%-98%), and recurrence-free survival was 84% (95% CI, 65%-93%). Four of 5 patients with persistent or recurrent disease posttreatment were successfully salvaged with total laryngectomy with 100% locoregional control. There were 11 mortalities (2 disease related, 2 due to metachronous primaries, 3 treatment related, and 4 from other/unknown causes). Conclusion Stage II laryngeal cancer has suboptimal survival outcomes. This appears to be a reflection of medical comorbidities, propensity for metachronous primaries, and the sequelae of late treatment effects rather than poor locoregional control.

Entities:  

Keywords:  early stage larynx cancer; laryngeal malignancy; laryngeal tumors; neoplasm; squamous cell carcinoma; stage II laryngeal cancer

Mesh:

Year:  2017        PMID: 28608731      PMCID: PMC5624831          DOI: 10.1177/0194599817711374

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  23 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Utility approach to decision-making in extended T1 and limited T2 glottic carcinoma.

Authors:  Yda van Loon; Anne M Stiggelbout; Marieke M Hakkesteegt; Ton P M Langeveld; Rob J Baatenburg de Jong; Elisabeth V Sjögren
Journal:  Head Neck       Date:  2017-02-15       Impact factor: 3.147

Review 3.  Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy.

Authors:  Kevin M Higgins; Manish D Shah; Maurice J Ogaick; Danny Enepekides
Journal:  J Otolaryngol Head Neck Surg       Date:  2009-12

4.  Survivorship in Head and Neck Cancer: A Primer.

Authors:  Matthew C Miller; Andrew G Shuman
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-10-01       Impact factor: 6.223

5.  T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy.

Authors:  W M Mendenhall; R J Amdur; C G Morris; R W Hinerman
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

6.  Oncologic and voice outcomes after treatment of early glottic cancer: transoral laser microsurgery versus radiotherapy.

Authors:  Paul Kerr; S Mark Taylor; Matthew Rigby; Candace Myers; Heather Osborn; Pascal Lambert; Donna Sutherland; Kevin Fung
Journal:  J Otolaryngol Head Neck Surg       Date:  2012-12

7.  T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy.

Authors:  D Howell-Burke; L J Peters; H Goepfert; M J Oswald
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-07

8.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

9.  Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation.

Authors:  Goshi Nishimura; Mamoru Tsukuda; Yasukazu Mikami; Hideki Matsuda; Choichi Horiuchi; Takahide Taguchi; Masahiro Takahashi; Mariko Kawakami; Makiko Watanabe; Tatsuo Niho; Hiroaki Abo; Sayaka Yamomoto
Journal:  Anticancer Res       Date:  2009-02       Impact factor: 2.480

10.  Transoral laser microsurgery for advanced laryngeal cancer.

Authors:  Michael L Hinni; John R Salassa; David G Grant; Bruce W Pearson; Richard E Hayden; Alexios Martin; Hans Christiansen; Bruce H Haughey; Brian Nussenbaum; Wolfgang Steiner
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.